Artivion, Inc. (NYSE: AORT) has received a consensus recommendation of “Moderate Buy” from nine analysts covering the stock, according to MarketBeat. The analysts’ ratings reflect a diverse outlook: one has issued a sell recommendation, one has a hold rating, and seven have expressed a buy sentiment. The average target price set by these analysts stands at approximately $49.11 for the next year.
Recent reports from several financial institutions highlight a positive trend for Artivion. On October 10, 2023, JMP Securities raised its target price for the company from $42.00 to $47.00, assigning a “market outperform” rating. Citigroup maintained an “outperform” rating for Artivion in the same week. Just a month later, on November 7, 2023, Oppenheimer also reaffirmed its “outperform” rating while setting a price objective of $50.00. Additionally, Citizens JMP increased its target price for the company to $53.00, reflecting growing confidence in Artivion’s market performance.
Artivion’s quarterly earnings results, announced on November 6, 2023, added to the positive sentiment. The company reported earnings per share (EPS) of $0.16, exceeding the consensus estimate of $0.14 by $0.02. Revenue for the quarter reached $113.39 million, surpassing analysts’ expectations of $110.71 million and marking an 18.9% increase compared to the previous year. Analysts anticipate the company will post an EPS of $0.37 for the current fiscal year.
Insider Transactions and Institutional Activity
In other developments, CEO James P. Mackin sold 34,210 shares of Artivion on November 13, 2023, at an average price of $45.86. This transaction totaled approximately $1.57 million, reducing his ownership stake by 4.10%. Post-transaction, Mackin retains 800,993 shares, valued at around $36.73 million. Senior Vice President Jean F. Holloway also sold 10,000 shares on November 11, 2023, for about $461,800, marking a 5.58% decrease in her holdings.
Overall, insiders sold a total of 234,511 shares during the last quarter, amounting to approximately $10.61 million. Currently, insiders hold 7.60% of the company’s stock.
Institutional investment trends show significant activity as well. Caitong International Asset Management Co. Ltd acquired a new stake in Artivion valued at about $27,000 during the third quarter. Aster Capital Management DIFC Ltd increased its stake by 402.3%, now holding 648 shares valued at $27,000. Similarly, USA Financial Formulas raised its holdings by 163.5%, now owning 1,133 shares valued at $52,000. Hedge funds and other institutional investors collectively own 86.37% of Artivion’s stock.
About Artivion, Inc.
Founded in 1984 as CryoLife, Artivion, Inc. has evolved into a global medical technology company specializing in the development and marketing of implantable tissue products and surgical devices for cardiac and vascular surgery. Its portfolio includes biologic implants derived from human and animal tissues, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are crucial for repairing and replacing damaged cardiovascular and thoracic tissues during various surgical procedures.
The company rebranded as Artivion in early 2022, reflecting its broader mission in cardiovascular innovation.
As Artivion continues to navigate the complexities of the medical technology sector, the recent ratings and financial results signal a robust outlook, highlighting the firm’s potential for growth in the coming year.
